Antituberculosis pharmaceutical composition

A composition and anti-tuberculosis technology, applied in the direction of antibacterial drugs, etc., can solve the problems of poor patient compliance, inability to kill tuberculosis bacteria, and the generation of drug-resistant strains, and achieve the effect of avoiding selective drug resistance

Inactive Publication Date: 2005-04-06
浙江南洋药业有限公司
View PDF0 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, most of the drugs used for tuberculosis are single drugs, and the anti-tuberculosis treatment takes a long time. Not only can tuberculosis bacteria not be killed, but also drug-resistant strains will be produced; and during routine treatment, patients must take corrected and sufficient anti-tuberculosis drugs , it is easy to cause sid

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0008] Example: Preparation of Tablets of Compositions of the Invention

[0009] formula:

[0010] Rifampicin 75.0g

[0011] Ethambutol Hydrochloride 137.5g

[0012] Isoniazid 37.5g

[0013] Pyrazinamide 200.0g

[0014] Microcrystalline Cellulose 50g

[0015] 70g pregelatinized starch

[0016] Magnesium Stearate 1.5g

[0017] Makes 1000 pieces

[0018] Weigh rifampicin, ethambutol hydrochloride, isoniazid, pyrazinamide, microcrystalline cellulose, pregelatinized starch, magnesium stearate according to the formula, mix well, press with a 12mm die to make tablets , and can also be film-coated to obtain film-coated tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an antituberculosis drug combination, prepared of rifampicin, isonicotinyl hydrazine, pyrazinamide, ethambutol hydrochloride and other auxiliaries, able to effectively overcome problems of drug resistance, improving compliance of patient, etc. It is applied in a compound form, which can avoid curing by single antituberculosis drug, thus avoiding selective drug resistance caused by single drug; the patients are willing to accept this, avoiding irregular drug application caused by simultaneously taking several drugs and different numbers of drug tablets, or taking more or less drugs.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to an anti-tuberculosis pharmaceutical composition. Background technique [0002] Tuberculosis is a chronic infectious disease. Unlike smallpox or polio, there is no guarantee that you will never get tuberculosis if you get vaccinated. According to information, in recent years, due to the relaxation of people's vigilance against tuberculosis, a large increase in poverty and floating population, as well as the emergence of drug-resistant strains and AIDS, tuberculosis has experienced a big rebound all over the world. The World Health Organization reports that tuberculosis is still the first killer of infectious diseases. About one-third (about 2 billion) people in the world are infected with tuberculosis. Among the existing 20 million tuberculosis patients, 95% are in developing countries. There are about 9 million new patients in the world every year, and 75...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4965A61P31/06
Inventor 谢元德陈春马越峰
Owner 浙江南洋药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap